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Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin
versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC)
From June 2006 to July 2009, 99 patients were randomized, 33 in each arm, by 16 institutions. The number of randomized/eligible pts who started 
treatment was 33/28 in A, 33/30 in PA and 33/30 in PE, respectively.  
RATIONALE OF EORTC 08062
STUDY DESIGN AND PATIENT FLOW
•	 Background:	Outcome	for	pts	with	ED	SCLC	remains	poor,	despite	standard	treatment	with	platinum	and	etoposide.	Amrubicin	is	a	synthetic	anthracycline 




 pts are required in an arm. 19 responses are needed in an arm in order to declare a success
 
CONCLUSION
This study shows that the combination arm, Amrubicin + Cisplatin was associated 
with the highest response rate. PFS and OS were similar in all arms. Based on the 
primary endpoint, further evaluation of this combination is warranted. All treatment 
groups had acceptable toxicity. Independent central review is still on going.(months)












O N Number of patients at risk : Treatment
27 28 17 12 4 3 2 1 0 0
28 30 24 18 5 1 1 1 1 1





Eligible patients who started treatment
Median in Months (95% 2-sided CI)
Amrub: 5.2 (3.0, 7.5) 
Amrub + Cisp: 6.9 (6.0, 7.5)
Cisp + Etop: 5.8 (5.3, 7.8)
PROGRESSION FREE SURVIVAL
(months)












O N Number of patients at risk : Treatment
26 28 26 22 14 12 5 2 0 0
22 30 28 22 16 10 7 3 2 1





Eligible patients who started treatment
Median in Months (95% 2-sided CI)
Amrub: 11.1 (7.9, 14.5) 
Amrub + Cisp: 11.1 (7.3, 16.3)
Cisp + Etop: 10.0 (9.2, 13.3)
OVERALL SURVIVAL














N (%) N (%) N (%) N (%)
 Sex                                           Male  19 (63)  21 (64)  21 (66)  61 (64) 
                                          Female  11 (37)  12 (36)  11 (34)  34 (37) 
 WHO Performance status               0  7 (23)  5 (15)  4 (12)  16 (17) 
                                                     1  19 (63)  22 (67)  23 (72)  64 (67) 
                                                     2  4 (13)  6 (18)  5 (16)  15 (16) 
Age category                 36 - 45 years    1 (3.3)                                 1 (3.0)                                 3 (9.4)                                 5 (5)                              
                                   46 - 55 years    7 (23.3)                                11 (33.3)                          7 (21.9)                                25 (26)                              
                                    56 - 65 years   15 (50.0)                                14 (42.4)                         15 (46.9)                         44 (46)                              
                                    66 - 75 years    5 (16.7)                                 6 (18.2)                                 7 (21.9)                                18 (19)                              
                                        > 75 years    2 (6.7)                                 1 (3.0)                                 0 (0.0)                                 3 (3)                              
Presence of non-malignant associated chronic disease     
 no  14 (47)  8 (24)  15 (47)  37 (39) 













Amrubicin relative dose intensity (%)    
 Median 91 90  
 Range 46 - 101 32 - 101  
Cisplatin relative dose intensity (%)    
 Median  89 89 
 Range  50 - 101 18 - 104 
Etoposide relative dose intensity (%)     
 Median   92 
 Range   46 - 133 
Number of cycles Received                                                                                              
 Median                                                   6               6               6               














N (%) N (%) N (%) N (%)
Best overall objective 
response (Investigator)
 PR  17 (61)  23 (77)  19 (63)  59 (67) 
 SD  6 (21)  2 (7)  4 (13)  12 (14) 
 PD  3 (11)  2 (7)  4 (13)  9 (10) 
 early death-toxicity  1 (4)  2 (7)  1 (3)  4 (5) 
 early death-other  0  0  2 (7)  2 (2) 
 not assessable  1 (4)  1 (3)  0  2 (2) 
The best overall response rates and their corresponding 1-sided 90% exact Confidence 
Intervals are 61% (47%, 100%), 77% (64%, 100%) and 63% (50%, 100%)  in A, PA 














N (%) N (%) N (%) N (%)
 WBC Grade 3  7 (23)  10 (30)  9 (28)  26 (27) 
Grade 4  8 (27)  9 (27)  3 (9)  20 (21) 
 Neutropenia Grade 3  8 (27)  7 (21)  10 (31)  25 (26) 
Grade 4  14 (47)  17 (52)  12 (38)  43 (45) 
 Thrombocytopenia Grade 3  4 (13)  3 (9)  3 (9)  10 (11) 
Grade 4  1 (3)  2 (6)  0  3 (3) 
 Anemia Grade 3  2 (7)  4 (12)  1 (3)  7 (7) 
Grade 4  1 (3)  1 (3)  0  2 (2) 
 Febrile neutropenia Grade 3  3 (10)  4 (12)  2 (6)  9 (10) 
Grade 4  1 (3)  1 (3)  0  2 (2) 
Hypotension Grade 3  1 (3.3)  0 (0.0) 1 (3.1) 2 (2.1)
Grade 4 0 (0.0) 1 (3.0) 0 (0.0)  1 (1.1)
Cardiac ischemia / infarction Grade 4  0 (0.0) 1 (3.0) 0 (0.0) 1 (1.1)
Mucositis / stomatitis Grade 3  2 (6.7) 2 (6.1) 1 (3.1) 5 (5.3)
Diarrhea Grade 3  0 (0.0) 2 (6.1) 2 (6.3) 4 (4.2)
Vomiting Grade 3  1 (3.3) 2 (6.1) 1 (3.1) 4 (4.2)
Neuropathy: motor Grade 3  0 (0.0) 0 (0.0) 1 (3.1) 1 (1.1)
Grade 4  0 (0.0) 1 (3.0) 0 (0.0) 1 (1.1)
Toxicity during treatment
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* All pts started treatment
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